Kumar Neil

Chief Executive Officer, DirectorBridgeBio Pharma, Inc. (BBIO) · full profile →Form 4 · filed May 11, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$5.4M
Net Open-Market Flow
-$5.4M
Transactions
12
12 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 8, 2026Sell(S)950$68.35$65K4.4M
May 8, 2026Sell(S)14K$66.65$931K562K
May 8, 2026Sell(S)5K$67.35$342K557K
May 8, 2026Sell(S)950$68.35$65K556K
May 8, 2026Sell(S)14K$66.65$931K4.4M
May 8, 2026Sell(S)5K$67.35$342K4.4M
May 7, 2026Sell(S)11K$67.50$757K584K
May 7, 2026Sell(S)8K$68.38$570K576K
May 7, 2026Sell(S)450$69.09$31K576K
May 7, 2026Sell(S)11K$67.49$757K4.4M
May 7, 2026Sell(S)8K$68.38$570K4.4M
May 7, 2026Sell(S)449$69.09$31K4.4M

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001470831-26-000423) within minutes of acceptance. Every field above traces to the original document. Verify it directly: